Piramal Critical Care is a global critical care company focused on saving lives with innovative critical care
solutions. The ability to build successful partnerships has always been an integral part of our growth story.
Since the inception of our parent company (PEL) over two decades ago, we have formed over 40 different business relationships with pharmaceutical companies, big and small, in various geographies and across a range of therapeutic areas including anesthesia, CNS, and pain.
Piramal Critical Care was built through strategic acquisitions over time, as and when the company was ready for the next phase of growth. Today, we are the third largest player in the Inhaled Anesthesia market and we are looking to expand our global footprint through new product additions in the generic hospital injectable space and other niche areas.
Our Business Development team leads the evaluation of assets and execution of agreements to support in- licensing, acquisitions, ANDA purchase, co-marketing/ promotion and similar strategic alliances. We currently seek opportunities that reflect our strategy, of driving success by leveraging our expertise, and looking ahead Piramal will continue to rely on strategic partnerships to create a robust portfolio of products to better serve patients and providers.
Areas of Interest:
- Hospital Critical Care drugs
- Neuromuscular blockers
- Muscle relaxants
- Vasoactive drugs
- Local anesthetics
- Other adjunct drugs (e.g . anti-emetics)
We are excited to hear from you! Please share ideas and opportunities by writing to firstname.lastname@example.org
Piramal Critical Care Footprint
With presence and experience in over 100 countries we offer access to a global marketplace
Partnering Workflow: How we work
At Piramal we understand that not one approach fits all, we offer flexibility and agility while working in collaboration with our partner to identify the most feasible approach towards deal closure. Our ability to provide fair assessment with quick turnaround times makes us a preferred partner.